Compare American Electric Power Company Inc (AEP) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Electric Power Company Inc vs Viatris Inc — how do they compare? American Electric Power Company Inc trades at $124.08 (market cap $67.28B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: American Electric Power Company Inc is far larger — about 3.6× Viatris Inc's market cap, and American Electric Power Company Inc pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| AEP | VTRS | |
|---|---|---|
Market Cap | $67.28B | $18.69B |
Sector | Utilities | Health |
52-Week High | $138.69 | $17.86 |
52-Week Low | $106.44 | $9.49 |
Enterprise Value | $120.17B | $30.80B |
Dividend Yield | 3.07% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Electric Power (AEP) trades at $123.89, up 0.85% today, with a bearish technical signal but strong analyst support. Recent Q2 2026 earnings missed estimates at $1.36 EPS versus $1.48 expected, though revenue grew 7% year-over-year. The company raised full-year 2026 operating EPS guidance to $6.25–$6.55, citing robust demand from data centers and a $78 billion capital plan. Valuation metrics include a P/E of 21.42 and P/B of 2.1, with a consensus price target of $140.89 implying 14% upside.
AEP's outlook is supported by contracted load growth and infrastructure investments, but risks include execution of its capital plan and interest expense pressures. The stock offers a dividend yield with an upcoming $0.95 payment. Analyst consensus is strongly bullish with 61% buy ratings, though technical indicators suggest near-term caution. Long-term growth targets of 7–9% annually provide a solid foundation for patient investors.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Electric Power Company Inc
American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 43% of AEP's of capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (19%), nuclear (7%), and demand response (4%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.
Read more on AEP →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
